Cardiology Year in Review: Most Popular Content of 2021

Top Stories of 2021

1. AHA/ASA Release Guidance for Treatment of COVID-19 Vaccine-Related Clotting, Low Platelet Counts
   The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.
   
2. Israeli Study Details Myocarditis Risk Associated with Pfizer COVID-19 Vaccine
   An analysis of more than 9 million patients, including more than 5 million receiving both doses, provides insight into the risks of myocarditis associated with the BNT162b2 COVID-19 vaccine.
   
3. FDA Approves Vericiguat (Verquvo) for Treatment of Heart Failure
   The US FDA has approved vericiguat (Verquvo) for reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in patients with HFrEF.
   
4. Meta-Analysis Raises Questions Around Risk of Atrial Fibrillation Associated with Omega-3 Supplements
   A meta-analysis and systematic review of 7 RCTs suggests consuming more than 1 gram of marine omega-3 fatty acid supplements per day could increase a patient's risk of atrial fibrillation.
   
5. FDA Approves Twice-Yearly Inclisiran (Leqvio) for Lowering Cholesterol in ASCVD, HeFH
   Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.